Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Finished Goods (2023 - 2025)

Historic Finished Goods for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q1 2025 value amounting to $15.5 million.

  • Iovance Biotherapeutics' Finished Goods rose 15329.97% to $15.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.5 million, marking a year-over-year increase of 15329.97%. This contributed to the annual value of $15.0 million for FY2024, which is 22472.42% up from last year.
  • As of Q1 2025, Iovance Biotherapeutics' Finished Goods stood at $15.5 million, which was up 15329.97% from $15.0 million recorded in Q4 2024.
  • In the past 5 years, Iovance Biotherapeutics' Finished Goods ranged from a high of $15.5 million in Q1 2025 and a low of $1.1 million during Q2 2023
  • For the 3-year period, Iovance Biotherapeutics' Finished Goods averaged around $7.9 million, with its median value being $5.5 million (2023).
  • In the last 5 years, Iovance Biotherapeutics' Finished Goods soared by 22472.42% in 2024 and then soared by 15329.97% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Finished Goods (Quarter) stood at $4.6 million in 2023, then skyrocketed by 224.72% to $15.0 million in 2024, then grew by 3.55% to $15.5 million in 2025.
  • Its Finished Goods was $15.5 million in Q1 2025, compared to $15.0 million in Q4 2024 and $6.1 million in Q1 2024.